<DOC>
	<DOCNO>NCT02657330</DOCNO>
	<brief_summary>This phase 1 first-in-human study evaluate safety tolerability SBP-101 subject previously treat pancreatic ductal adenocarcinoma identify maximum tolerate dose ( MTD ) . In addition , study also assess pharmacokinetic ( PK ) profile preliminary efficacy SBP-101 .</brief_summary>
	<brief_title>Study SBP-101 Pancreatic Cancer</brief_title>
	<detailed_description>This first-in-human study SBP-101 conduct two phase : dose escalation expansion . The dose escalation phase study evaluate safety , tolerability PK profile SBP-101 subject previously treat locally advanced metastatic pancreatic ductal adenocarcinoma . Up 48 subject may enrol dose escalation . The expansion phase study consist 24 additional subject receive maximum tolerate dose SBP-101 base data dose escalation phase study .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Histologically cytologically confirm locally advanced metastatic pancreatic ductal adenocarcinoma . Patients acinar cell carcinoma may also include . Measurable disease CT MRI scan RECIST criterion ( require Phase 1b ) . ECOG Performance Status 0 1 . Received fail , intolerant , least 1 prior systemic therapy locally advance metastatic pancreatic ductal adenocarcinoma . Adult , least 18 year age , male female Females childbearing potential must negative serum pregnancy test within 14 day prior start study treatment must use adequate method contraception study . All sexually active male must also use adequate method contraception study . Adequate bone marrow , hepatic , renal coagulation function define follow : Absolute neutrophil count ≥1.5 x 10^9/L , Hemoglobin ≥9.0 g/dL ( 90 g/L ) , Platelets ≥100 x 10^9/L , Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤2.5 x upper limit normal ( ULN ) ( hepatic metastasis ) . If hepatic tumor involvement , AST ALT ≤5 x ULN , Bilirubin ≤1.5 x ULN , Prothrombin time ( PT ) / international normalize ratio ( INR ) ≤1.5 x ULN , Calculated creatinine clearance &gt; 50 mL/min use Cockcroft Gault equation QTc interval ≤ 470 msec Baseline Willing able provide write informed consent : voluntary agreement participate study follow disclosure risk procedure require , include possibility onset exocrine pancreatic insufficiency subsequent requirement lifelong pancreatic enzyme replacement Evidence severe uncontrolled systemic disease concurrent condition , opinion Investigator Medical Monitor , make undesirable subject participate study would jeopardize compliance protocol . Subjects preexist wellcontrolled diabetes exclude . Medical psychiatric condition compromise subject 's ability give inform consent complete protocol history noncompliance Presence isletcell pancreatic neuroendocrine tumor mixed adenocarcinomaneuroendocrine carcinoma Have symptomatic central nervous system ( CNS ) malignancy metastasis . Screening asymptomatic subject without history CNS metastases require . Serum albumin &lt; 30 g/L ( 3.0 g/dL ) Glycosylated hemoglobin ( Hgb A1C ) &gt; 8.0 % Life expectancy &lt; 16 week Presence know active bacterial , fungal , viral infection require systemic therapy Known infection human immunodeficiency virus ( HIV ) , hepatitis B C Presence interstitial lung disease , pulmonary fibrosis , pulmonary hypersensitivity reaction Myocardial infarction within last 12 month , severe/unstable angina , symptomatic congestive heart failure , New York Heart Association ( NYHA ) class III IV Maldigestion/malabsorption syndrome predate diagnosis pancreatic cancer . Known , exist coagulopathy receive anticoagulant Pregnant lactate Major surgery within 4 week start study treatment , without complete recovery Participation clinical investigation within 4 week receive first dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Locally Advanced</keyword>
	<keyword>Metastatic</keyword>
</DOC>